These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20023047)

  • 21. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Perez-Moreno AC; Jhund PS; Macdonald MR; Petrie MC; Cleland JG; Böhm M; van Veldhuisen DJ; Gullestad L; Wikstrand J; Kjekshus J; Lewsey JD; McMurray JJ
    JACC Heart Fail; 2014 Apr; 2(2):187-97. PubMed ID: 24720928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
    Ohsfeldt RL; Gandhi SK; Smolen LJ; Jensen MM; Fox KM; Gold A; Hsia J
    J Med Econ; 2010; 13(3):428-37. PubMed ID: 20662625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):427-36. PubMed ID: 20805548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the answer to the cholesterol paradox in heart failure?
    Velavan P; Loh PH; Clark A; Cleland JG
    Congest Heart Fail; 2008; 14(1):55. PubMed ID: 18256572
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study).
    van der Harst P; Slart RH; Tio RA; Dunselman PH; Willemsen AT; van den Heuvel AF; Voors AA; van Veldhuisen DJ;
    Am J Cardiol; 2010 Feb; 105(4):517-21. PubMed ID: 20152247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
    McMurray JJ; Dunselman P; Wedel H; Cleland JG; Lindberg M; Hjalmarson A; Kjekshus J; Waagstein F; Apetrei E; Barrios V; Böhm M; Kamenský G; Komajda M; Mareev V; Wikstrand J;
    J Am Coll Cardiol; 2010 Oct; 56(15):1196-204. PubMed ID: 20883926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
    Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
    Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [To treat or not to treat with statins patients with chronic heart failure?].
    Hradec J
    Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
    Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
    Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Choosing wisely when prescribing statins].
    Willemsen AE; Bredie SJ; Lobo CM; van der Vlugt MJ; Kramers C
    Ned Tijdschr Geneeskd; 2015; 159():A8695. PubMed ID: 25990330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
    Abdul-Rahim AH; Perez AC; Fulton RL; Jhund PS; Latini R; Tognoni G; Wikstrand J; Kjekshus J; Lip GY; Maggioni AP; Tavazzi L; Lees KR; McMurray JJ; ;
    Circulation; 2015 Apr; 131(17):1486-94; discussion 1494. PubMed ID: 25810334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rosuvastatin in patients with chronic heart failure].
    Hoppe UC; Nitschmann S
    Internist (Berl); 2009 Apr; 50(4):501-2. PubMed ID: 19300974
    [No Abstract]   [Full Text] [Related]  

  • 38. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
    Martikainen JE; Saastamoinen LK; Korhonen MJ; Enlund H; Helin-Salmivaara A
    Med Care; 2010 Sep; 48(9):761-6. PubMed ID: 20706164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
    N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.